Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesA Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
Clinical Cancer Research, 09/15/09
Demetri GD et al. – Nilotinib alone or in combination with imatinib was well tolerated overall and showed clinical activity in imatinib–resistant gastrointestinal stromal tumor patients. This phase I trial identified single–agent nilotinib 400 mg bid or combined with imatinib 400 mg qd as possible phase II doses for further evaluation.
Related Articles
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Blood, 10/30/09
Relevance Score: 89%
Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells
Cancer Chemotherapy and Pharmacology, 11/04/09
Relevance Score: 85%
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL + cell to Imatinib and Nilotinib
Leukemia and Lymphoma, 10/30/09
Relevance Score: 80%
Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia
Haematologica, 10/21/09
Relevance Score: 77%
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)
Medical Oncology, 12/04/09
Clinicopathological characteristics of primary gastric T-cell lymphoma
Histopathology, 12/04/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor